Discovery of Dual Leucine Zipper Kinase (DLK, MAP3K12) Inhibitors with Activity in Neurodegeneration Models
Authors:
- Frederick CohenFCFrederick Cohen
- Brian J. DeanBDBrian J. Dean
- Kelly De La TorreKTKelly De La Torre
- Gauri DeshmukhGDGauri Deshmukh
- Anthony A. EstradaAEAnthony A. Estrada
- Arundhati Sengupta GhoshAGArundhati Sengupta Ghosh
- Paul GibbonsPGPaul Gibbons
- Amy GustafsonAGAmy Gustafson
- Malcolm P. HuestisMHMalcolm P. Huestis
- Claire E. Le PichonCPClaire E. Le Pichon
- Han LinHLHan Lin
- 23 October 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (1) , 401-418
Abstract
Dual leucine zipper kinase (DLK, MAP3K12) was recently identified as an essential regulator of neuronal degeneration in multiple contexts. Here we describe the generation of potent and selective DLK inhibitors starting from a high-throughput screening hit. Using proposed hinge-binding interactions to infer a binding mode and specific design parameters to optimize for CNS druglike molecules, we came to focus on the di(pyridin-2-yl)amines because of their combination of desirable potency and good brain penetration following oral dosing. Our lead inhibitor GNE-3511 (26) displayed concentration-dependent protection of neurons from degeneration in vitro and demonstrated dose-dependent activity in two different animal models of disease. These results suggest that specific pharmacological inhibition of DLK may have therapeutic potential in multiple indications.Keywords
This publication has 61 references indexed in Scilit:
- JNK2 and JNK3 are major regulators of axonal injury-induced retinal ganglion cell deathNeurobiology of Disease, 2012
- Protein Kinase−Inhibitor Database: Structural Variability of and Inhibitor Interactions with the Protein Kinase P-LoopJournal of Proteome Research, 2010
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike PropertiesACS Chemical Neuroscience, 2010
- Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety AttributesACS Chemical Neuroscience, 2010
- Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural DatabaseJournal of Chemical Information and Modeling, 2010
- Cross-Coupling of Cyclopropyl- and Cyclobutyltrifluoroborates with Aryl and Heteroaryl ChloridesThe Journal of Organic Chemistry, 2008
- Efficient Cross-Coupling of Secondary Alkyltrifluoroborates with Aryl Chlorides—Reaction Discovery Using Parallel Microscale ExperimentationJournal of the American Chemical Society, 2008
- A New Class of Easily Activated Palladium Precatalysts for Facile C−N Cross-Coupling Reactions and the Low Temperature Oxidative Addition of Aryl ChloridesJournal of the American Chemical Society, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Pathways towards and away from Alzheimer's diseaseNature, 2004